A study has found the high bilirubin, pretreatment hypoalbuminemia, and biochemical tests indicative of hepatic or renal dysfunctions are independently associated with short-term mortality in patients with advanced hepatocellular cancer (HCC) receiving atezolizumab and bevacizumab (Atezo/Bev).
A novel risk score, PAGED-B, may be used to predict hepatocellular carcinoma (HCC) development at the time of transition into hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), suggests a study.
In cirrhosis patients with acute variceal bleeding (AVB), treatment with terlipressin for a single day yields similar rebleeding and mortality rates as 3-day treatment following endoscopic haemostasis, while having an overall superior safety profile, according to a study.
The incidence of hepatocellular carcinoma (HCC) remains low in patients with autoimmune hepatitis (AIH) even after developing cirrhosis, according to a study. Factors such as obesity, cirrhosis, and AIH/primary sclerosing cholangitis (PSC) variant syndrome can increase the risk of HCC incidence.
People who consume a lot of ultra-processed food (UPF) have a greater risk of developing nonalcoholic fatty liver disease (NAFLD), liver fibrosis, and cirrhosis, as well as severe liver disease and adverse levels of several clinical biomarkers, reveals a study.
The risk of osteoporotic fracture seems greater in patients with autoimmune hepatitis (AIH), reveals a recent study. In addition, those with cirrhosis and long-term use of glucocorticoids appear to be at much greater risk.